Combination therapy for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests two drugs together to see if they can help people with multiple myeloma that has come back after other treatments. It aims to shrink or control the cancer and may offer a new option for patients who have already tried several therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma and have already tried at least 3 different types of treatment.
- You should be generally able to take care of yourself (performance status 0, 1, or 2).
- Your cancer must be measurable by blood or urine tests.
- You must have had some treatments like daratumumab, lenalidomide, bortezomib, or CAR-T cells and they stopped working.
- You must not have certain eye problems and you can't wear contact lenses while on the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.